Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
Portfolio Pulse from Vandana Singh
H.C. Wainwright has initiated coverage on Anebulo Pharmaceuticals Inc (NASDAQ:ANEB) with a Buy rating and a price target of $6. The company is focused on developing therapy for acute cannabinoid intoxication (ACI) and has produced compelling clinical proof-of-concept data. The analysts note that positive pivotal data for ANEB-001 could make Anebulo an attractive acquisition target. ANEB-001 could be priced at $2.5K per administration and may ultimately achieve total sales approaching $500 million in the U.S. alone.
September 18, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anebulo Pharmaceuticals has received a Buy rating from H.C. Wainwright, with a price target of $6. The company's focus on ACI therapy and the potential of ANEB-001 could make it an attractive acquisition target.
The Buy rating from H.C. Wainwright indicates a positive outlook for Anebulo Pharmaceuticals. The company's focus on ACI therapy and the potential of ANEB-001, which could achieve total sales approaching $500 million in the U.S., makes it an attractive acquisition target. This could lead to a potential increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100